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Abstract.
Objectives: To investigate the role of fluid intake from beverages before and after a diagnosis of bladder cancer in relation
to the risk of developing bladder cancer recurrence.
Study Design: Prospective cohort study.
Methods: 716 patients with non-muscle invasive bladder cancer (NMIBC), who received transurethral resection of a primary
bladder tumour (TURBT) and completed self-administrated questionnaires on usual fluid intake from beverages at time of
diagnosis (over the year before diagnosis) and during follow-up (over the year after diagnosis), were included. Multivariable
Cox regression was used to calculate hazard ratios and 95% confidence intervals of developing recurrent bladder cancer in
relation to the intake of total fluid, total alcohol, and individual beverages.
Results: During 2,025 person-years of follow-up, 238 (33%) of the included 716 NMIBC patients developed one or more
recurrences of bladder cancer. Total fluid intake before diagnosis was not associated with a first recurrence of bladder cancer
when comparing the highest and lowest intake group (HR = 0.98, 95% C.I. 0.70–1.38, p = 0.91). Comparable results were
obtained for total fluid intake pre-diagnosis and the risk of developing multiple recurrences of bladder cancer (HR = 1.01,
95% C.I. 0.87–1.19, p = 0.85). A total of 379 of the 716 patients reported on usual fluid intake within 1 year of diagnosis. No
significant associations between total fluid intake 1 year after diagnosis and a first recurrence of bladder cancer were found
when comparing the highest and lowest intake group (HR = 0.91; 95% C.I. 0.60–1.37, p = 0.65) or with multiple recurrences
of bladder cancer (HR = 1.06; 95% C.I. 0.89–1.26, p = 0.54). In addition, total alcohol intake and individual beverages were
not associated with bladder cancer recurrence.
Conclusions: The results indicate that an individual’s fluid intake from beverages is unlikely to have an important role in
bladder cancer recurrence.
Keywords: Fluid intake, bladder cancer, recurrence
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INTRODUCTION
Non-muscle-invasive bladder cancer (NMIBC) is
the most common malignancy of the urinary tract and
has a high rate of recurrence despite adequate therapy.
Identification of modifiable risk factors could reduce
the risk of developing recurrences and improve prog-
nosis. The urogenous contact theory hypothesizes
that an increased voiding frequency may reduce blad-
der cancer risk [1, 2]. By increasing the intake of
fluids, potential carcinogens present in the urine
are diluted and the voiding frequency stimulated.
By reducing the contact time of carcinogens with
the bladder urothelium, the risk of bladder cancer
decreases. On the contrary, it has been suggested that
when the bladder wall is extended from a high vol-
ume of urine, carcinogens can come into contact with
deeper layers of the bladder urothelium and increase
bladder cancer risk [3]. In addition, in some parts of
the world drinking water contaminated with a high
concentration of arsenic could increase the risk of
bladder cancer [4]. It is conceivable that the theories
about fluid intake and the risk of developing bladder
cancer represent a modifiable factor of importance in
bladder cancer prognosis as well [5–7]; it would be a
compelling strategy to simply increase or decrease
fluid intake to decrease the risk of recurrence. To
our knowledge, only Donat et al. [8] investigated
the impact of total fluid intake on tumour recurrence
in patients with NMIBC. At each visit, all patients
undergoing surveillance for recurring tumours com-
pleted a self-administered fluid intake questionnaire
that measured total fluid intake during a 24-hour
period. Results of this study indicated that daily fluid
intake levels did not affect recurrence and that the
types of fluids imbibed may be more important than
the total amount [8]. Therefore, the present study
investigates the role of individual beverages, total
alcohol and total fluid intake (over the year before and
the year after diagnosis) and the risk of developing
one or more recurrences of bladder cancer.
METHODS
The bladder cancer prognosis programme
This study is part of the Bladder Cancer Progno-
sis Programme (BCPP), a prospective cohort study
in the West Midlands region of England. Details
of the cohort have been published previously [9].
Briefly, during the enrolment period (December
2005–October 2011), a total of 1,550 male and female
patients (age ≥18 years) were enrolled based on
abnormal cystoscopic findings suggestive of bladder
cancer. Transurethral resection of the primary blad-
der tumour (TURBT) was followed by cytoscopic
surveillance. Optimal additional treatment comprised
intravesical chemotherapy with mitomycin C within
24 hours of TURBT and/or a course of further
mitomycin C or intravesical BCG, as per contem-
porary European Association of Urology guidelines.
Bladder cancer recurrence was defined as the new
occurrence of a non-muscle invasive bladder cancer
(stage Ta, T1, or pTis) at the same or at a differ-
ent site as the initial primary bladder tumour and
excluding recurrence identified at the first check cys-
toscopy. Written informed consent was obtained from
all participants. The study protocol was approved
by the Nottingham Research Ethics Committee
(06/MRE04/65) and registered on ClinicalTrials.gov
(NCT00553566).
Data collection
Around the time of diagnosis, just prior to, or
just post TURBT, data on medical history, socio-
demographics, quality of life, and health-related
lifestyle (including dietary intake) were collected by
a trained research nurse using semi-structured face-
to-face interviews and a questionnaire. The research
nurse and patient went through the questionnaire
page by page. Patients were asked about habitual
dietary intake over the previous year. The developed
version of the food-frequency questionnaire (FFQ)
aims to assess the dietary intake, by asking the par-
ticipants to report the frequency of consumption of
approximately 16-line items over the last year. More
specifically, the frequency of fluid intake from bev-
erages asked in the questionnaire consisted of six
levels: never or less than once per month, one to three
times per month, once a week, two to four times per
week, five to six times per week, or at least once
per day. For each drink, a measure size was pro-
vided (e.g. cup, (small) glass, pub measure (2.5cl),
or (half) pint glass). The frequency of intake of each
beverage was multiplied by their measure size to cal-
culate the millilitres of fluids consumed per day. Total
fluid intake was computed as the sum of servings of
all beverages in the questionnaire: wine-champagne,
fortified wine, beer, cider, spirits, liqueurs, coffee,
tea, hot chocolate, soup, ovaltine-horlicks, fizzy pop,
pure fruit juice, fruit squash, milk, and water. Total
alcohol intake included alcoholic beverages only:
wine-champagne, fortified wine, beer, cider, spirits,
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and liqueurs. Repeated fluid intake from beverages
was collected through a postal follow-up question-
naire one year after diagnosis.
Exclusion criteria
A total of 244 participants with no evidence of a
bladder tumour (T0), patients who had a tumour that
could not be assessed (Tx) (n = 116), who had mus-
cle invasive bladder cancer (MIBC) (n = 275), who
received no TURBT (n = 16), who had radiotherapy
(on suspicion of MIBC) (n = 8), who had incomplete
data on tumour characteristics (e.g. stage, grade, size,
multiplicity) (n = 53) and smoking (n = 94), and had
missing data on pre-diagnosis fluid intake (n = 28),
were all excluded from this study (Fig. 1). The final
analysis for fluid intake over the year before diagno-
sis comprised 716 patients. More than a third of these
716 patients did not complete a follow-up question-
naire one year after diagnosis (n = 278) or developed
a recurrence of bladder cancer before completing the
follow-up questionnaire (n = 59). Therefore, a total of
379 patients remained for investigating the associa-
tion between fluid intake over the year after diagnosis
and bladder cancer recurrence.
Statistical analysis
According to the UK government recommenda-
tions on eating healthy and achieving a balanced
diet, anybody living in a maritime climate should
consume at least 1,200 mL of fluids from drinks a
day [10]. Patients were divided into three groups: a
group with an intake of 250 mL –850 mL of total fluid
per day, a group consuming 850 mL –1,200 mL of
total fluid per day, or a group with a total intake of
more than the recommended 1,200 mL of fluid per
day. Patients became at risk for a recurrence of blad-
der cancer from the date of TURBT and remained
at risk until the earliest occurrence of a recurrence,
cystectomy, death, the most recent surveillance cys-
toscopy, or study end (five years post-TURBT). Cox
regression was used to calculate hazard ratios (HRs)
and 95% confidence intervals (95% C.I.) of devel-
oping a first recurrence of bladder cancer in relation
to total fluid intake, total alcohol intake, and individ-
ual beverages. To identify possibly influential outliers
in total fluid and alcohol intake, Cook’s Distance
was used. The association of fluid intake with recur-
rent bladder cancer was examined in both crude
and multivariate models. Confounders were consid-
ered a priori based on known prognostic factors
for NMIBC recurrence from the European Asso-
ciation of Urology guidelines and included: age
at diagnosis (continuous) [11], sex (male/female)
[12], smoking status (never/former/current smoker)
[13], and tumour characteristics including stage
(pTa/pT1/pTis), grade (1/2/3), size of largest tumour
(diameter <3 cm/≥3 cm), and tumour multiplicity
(1/>1) [14–16].
Conditional risk set modelling was applied to
investigate time to each recurrent event and analysis
time was reset at each event [17]. For this anal-
ysis, re-resection of tumours (yes/no) was added
as a confounder. The proportional hazards assump-
tion was checked in all models using Schoenfeld
residuals [18]. Cumulative incidence functions (CIF)
accounting for competing risks (death and cystec-
tomy) were made [19]. These models are conditional
as the failure times are conditional on the occurrence
of the prior recurrence, i.e. a second recurrence can-
not occur before the first recurrence. P-values were
2-sided with a significance level of 0.05. All statis-
tical analyses were performed using Stata software
version 14.
RESULTS
Baseline characteristics and number of
recurrences
During 2,025 person-years of follow-up (mean
(SD) follow-up 3.7 (1.5) years), 238 (33%) of the 716
NMIBC patients developed one or more recurrences
of bladder cancer. More specifically, 80 (34%) of
these 238 patients developed a second recurrence, 35
(15%) a third recurrence, 17 (8%) a fourth recurrence,
five (3%) a fifth recurrence, two (1%) a sixth recur-
rence, and one (1%) a seventh recurrence. Patient
characteristics at diagnosis and initial treatment are
presented in Table 1. The median age at diagnosis was
71 years and most patients were male (80%), Cau-
casian (97%), and current or former smokers (86%).
The average intake of fluid was relatively evenly dis-
tributed between patients who had a recurrence of
bladder cancer and those who had not (mean total
fluid intake 1,087 mL per day and 1,103 mL per day,
respectively).
Total ﬂuid intake and bladder cancer recurrence
Table 2 presents HRs with corresponding 95%
C.I. for total fluid intake over the year before diag-
nosis from beverages and time to a first bladder
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Fig. 1. Flow diagram of patients selection, with exclusion criteria.
cancer recurrence and multiple bladder cancer recur-
rences among 716 NMIBC patients. Total fluid intake
the year before diagnosis did not affect the recur-
rence of a first bladder tumour (HR = 0.98, 95%
C.I. 0.70–1.38, p = 0.91) when adjusted for age,
sex, smoking status, stage, grade, and tumour size
and multiplicity. The association between total fluid
intake the year before diagnosis and time to multi-
ple recurrences showed similar results (HR = 1.01,
95% C.I. 0.87–1.19, p = 0.85) when adjusted for the
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Table 1
Patient characteristics at diagnosis for 716 NMIBC patients treated with transurethral resection of a primary bladder tumour
Number (%)
Age at time of diagnosis (years) median (25th–75th percentile) 71 (63–77)
Sex Male 573 (80%)
Female 143 (20%)
Smoking status Current smokers 335 (47%)
Former smokers 281 (39%)
Never smokers 100 (14%)
Alcohol consumption Drinkers 540 (75%)
Non-drinkers 176 (25%)
Educational level High 89 (12%)
Middle 91 (13%)
None/Low 163 (23%)
BCG intravesical immunotherapy Yes 111 (15%)
No 275 (39%)
Mitomycin C intravesical chemotherapy Yes 337 (47%)
No 73 (10%)
Tumour stage pTa 478 (67%)
pT1 232 (32%)
pTis 6 (1%)
Tumour grade 1 206 (29%)
2 261 (36%)
3 249 (35%)
Size largest tumour (cm) <3 449 (63%)
≥3 267 (37%)
Tumours multiplicity 1 427 (59%)
>1 289 (41%)
No of recurrences over 5 years 0 478 (67%)
1 158 (22%)
>1 80 (11%)
Where the data contains missing values the percentages do not add up to 100%.
same confounders and tumour re-resection (second
transurethral resection).
Table 3 presents the results for the remaining 379
NMIBC patients on total fluid intake after diag-
nosis – no significant associations were observed
between total fluid intake and the development of
a first bladder cancer recurrence (HR = 0.91; 95%
C.I. 0.60–1.37, p = 0.65) or multiple recurrences
(HR = 1.06; 95% C.I. 0.89–1.26, p = 0.54) when cor-
rected for known prognostic factors for NMIBC
recurrence provided in the European Association of
Urology guidelines (including age, sex, smoking sta-
tus, tumour characteristics and tumour re-resection).
Total alcohol and individual beverages intake
and bladder cancer recurrence
Results of the Cox proportional hazard models
predicting the development of recurrence based on
total alcohol intake and individual beverages can
be found in the online supplementary file (Tables
S1–S8). Among 716 NMIBC patients, total alcohol
intake before diagnosis (highest intakes >125 mL ver-
sus lowest intakes 0 mL) was not associated with a
first bladder tumour (HR = 0.97; 95% CI 0.70–1.36)
in the most extensive model (adjusted for age, sex,
smoking status, stage, grade, and tumour size and
multiplicity) (Table S1). Similar results were found
for total alcohol intake prior to a diagnosis of blad-
der cancer and multiple recurrences of bladder cancer
(HR = 0.97; 95% CI 0.84–1.11) when corrected for
the same confounders as in the time to a first recur-
rence analysis plus re-resection of a bladder tumour
(Table S2).
None of the individual alcoholic beverages includ-
ing beer, cider, wine/champagne, fortified wine,
spirits or liqueurs consumed prior to bladder cancer
diagnosis influenced the risk of developing a first or
multiple recurrences of bladder cancer when compar-
ing the highest frequency of intake ‘at least 1 per day’
versus the lowest frequency of intake /never/less than
1 per month’ (Tables S1-S2). The warm beverages
coffee, tea, hot chocolate, ovaltine/horlicks and soup
were also investigated. No associations were found
when comparing the frequencies of these warm bev-
erages (at least one per day versus never/less than
1 per month before diagnosis) and a first or multi-
ple recurrences of bladder cancer (Tables S3-S4). In
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Table 2
Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences
of bladder cancer, based on total fluid intake over the year before diagnosis, in 716 NMIBC patients
Model 1∗ Model 2∗∗ Model 3∗∗∗
n events HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value p for trend
Time to first recurrence
250–850 mL 205 64 ref ref ref 0.86
850–1200 mL 257 98 1.24 (0.90–1.69) 0.19 1.26 (0.92–1.72) 0.16 1.17 (0.85–1.62) 0.33
>1200 mL 254 76 0.92 (0.66–1.28) 0.62 0.93 (0.67–1.31) 0.70 0.98 (0.70–1.38) 0.91
Time to multiple recurrences
250–850 mL 205 92 ref ref ref 0.78
850 – 1200 mL 257 171 0.95 (0.83–1.09) 0.48 0.96 (0.84–1.10) 0.57 0.95 (0.83–1.08) 0.42
>1200 mL 254 115 1.05 (0.90–1.22) 0.51 1.05 (0.90–1.23) 0.54 1.01 (0.87–1.19) 0.85
∗Model 1 is unadjusted, ∗∗Model 2 is adjusted for age, sex, and smoking status, ∗∗∗Model 3 is adjusted for age, sex, smoking status, tumour
stage, grade, size and multiplicity. In the time to multiple recurrences analyses, Model 2 and Model 3 were additionally adjusted for the
variable re-resection of a bladder tumour (second transurethral resection).
Table 3
Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences
of bladder cancer, based on total fluid intake over the year after diagnosis, in 379 remaining NMIBC patients
Model 1∗ Model 2∗∗ Model 3∗∗∗
n Events HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value p for trend
Time to first recurrence
250–850 mL 116 45 ref ref ref 0.65
850–1200 mL 124 48 1.08 (0.72–1.63) 0.71 1.04 (0.69–1.57) 0.86 1.07 (0.71–1.61) 0.76
>1200 mL 139 46 0.81 (0.54–1.21) 0.31 0.80 (0.53–1.20) 0.27 0.91 (0.60–1.37) 0.65
Time to multiple recurrences
250–850 mL 116 67 ref ref ref 0.53
850–1200 mL 124 71 1.07 (0.91–1.25) 0.41 1.06 (0.91–1.24) 0.43 1.08 (0.91–1.27) 0.38
>1200 mL 139 68 1.05 (0.87–1.26) 0.63 1.04 (0.86–1.26) 0.67 1.06 (0.89–1.26) 0.54
∗Model 1 is unadjusted, ∗∗Model 2 is adjusted for age, sex, and smoking status, ∗∗∗Model 3 is adjusted for age, sex, smoking status, tumour
stage, grade, size and multiplicity. In the time to multiple recurrences analyses, Model 2 and Model 3 were additionally adjusted for the
variable re-resection of a bladder tumour (second transurethral resection).
addition, pre-diagnosis consumption of the cold bev-
erages milk, water, fizzy pop, pure fruit juice, and
fruit squash/cordial, did not affect the development of
one or multiple recurrences of bladder cancer when
comparing the highest versus the lowest frequency
intakes.
Among the 379 NMIBC that remained for analy-
ses one year after a diagnosis of bladder cancer, total
alcohol intake was not associated with a first recur-
rence (HR = 1,01; 95% CI 0.65–1.58) or multiple
recurrences (HR = 1,05; 95% CI 0.88–1.25) (Tables
S5-S6). Consumption of alcoholic beverages one year
after a diagnosis of bladder cancer was not related
to the development of bladder cancer recurrences
(Tables S5-S6). Finally, no associations were found
for usual warm and hot non-alcoholic beverages con-
sumption and one or more recurrence of bladder
cancer (Tables S7-S8).
DISCUSSION
The results of this study indicate that there is no
evidence of an association between total fluid, total
alcohol, or individual beverages (before and after
diagnosis) and recurrence of a bladder tumour in
patients diagnosed for NMIBC. These results are con-
sistent with the findings of Donat et al. [8] who also
concluded it remains unclear whether increased total
fluid intake is beneficial against the development of
bladder cancer recurrence. With regard to fluid intake
and the risk of developing bladder cancer for the
first time, the results of a recent case-control study
have shown that there was no association with total
water intake from both beverages and foods [20].
Also the results of a meta-analysis demonstrated no
association between total fluid intake and the risk of
developing primary bladder cancer [21]. However,
subgroup analyses indicated that high fluid intake
could increase the risk of bladder cancer in European
men (and possibly American men) and decrease the
risk of bladder cancer in Asian men [21].
It seems plausible, however, that substances in
beverages could be involved in carcinogenesis in
the bladder as they come into contact with the
bladder urothelium when excreted via the urine.
The numerous substances may react differently with
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cells of the bladder urothelium and be involved in
several different pathways associated with cancer
pathogenesis including inflammation, cell survival
and self-renewal of cancer stem cells [22, 23]. A
possible explanation for the lack of an association
between fluid intake from beverages and bladder can-
cer recurrence could be that tumour recurrence is
more influenced by tumour biology, field canceriza-
tion, and cancer treatment than continued exposure
of potential carcinogens with the bladder urothe-
lium [24–26]. Incomplete resection of the primary
tumour and tumour cell re-implantation remain to
be the most influential factors in the development
of NMIBC recurrence [26]. Finally, it is inevitable
that fluid intake was not measured without error -
recall bias and measurement errors in dietary intake
cannot be excluded and are a common limitation of
epidemiological studies.
CONCLUSIONS
The results of this study indicate that fluid intake
from beverages is unlikely to have a dominant role
in influencing the risk of subsequent recurrence(s).
Proposed strategies aimed at decreasing contact time
of carcinogens with the urothelium by increasing
fluid intake are unlikely to delay or prevent the
development of bladder cancer recurrence in NMIBC
patients.
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